About Us

Company Founders

Dr. Aurélie Joly-Amado is a scientific leader with over 15 years of experience in neuroscience, metabolic disease, and biotech innovation. She earned her Ph.D. from Université Paris Cité, focusing on the role of the central nervous system in metabolic disorders. Her work bridges research and clinical development, contributing to novel therapeutic strategies and cross-functional team leadership. She brings a unique blend of scientific rigor and strategic insight into veterinary and biomedical applications.

She’s had cats, pet rats and hamsters in the past and now lives with Shushu, the guinea pig.

---

Marselina, a summa cum laude graduate from the University of South Florida, earned her B.S. in Cellular and Molecular Biology. She has worked alongside Dr. Kevin Nash and Dr. Aurélie Joly-Amado in research focused on Alzheimer’s disease since 2022, and more recently, metabolic disorders like diabetes. Her goal is to become a clinician-scientist dedicated to advancing treatments for complex diseases. With a strengthening foundation in both veterinary medicine and scientific research, she is committed to bridging the gap between practice and discovery.

She has owned pets all her life and currently has 5 cats who she is a proud pet parent to, all stray rescues that she has taken in from her community.

---

Dr. Kevin Nash is a neuroscientist with over 20 years of experience in gene therapy, neuroinflammation, and neurodegenerative disease research. His work bridges molecular biology, virology, and translational neuroscience, with a long-standing focus on understanding and treating disorders such as Alzheimer’s, Parkinson’s, Angelman syndrome, and Fragile X syndrome.

He has pioneered research in the adeno-associated virus (AAV) field, including the development of novel delivery methods and therapeutic constructs that have advanced toward clinical trials. Collectively, these efforts reflect a translational research program aimed at developing innovative therapies for complex neurological disorders.

---

Professor Christian Bréchot holds MD and PhD degrees. He has served as President of  Inserm, the French National Agency for biomedical research (“French NIH”), then  Vice-President of Medical and Scientific Affairs of the Institut Merieux company, and then President of the Institut Pasteur. Since 2018, he is a full Professor with tenure at the University of South Florida in Tampa (Senior Associate Dean for Research on Global Affairs and Associate Vice-President for International Partnerships and Innovation) and Vice-Chair and Emeritus President of the Board of the Global Virus Network. Also, he is Chief Medical Officer of the Theravectys company, and founder and chairman of The Healthy Aging Company.

Dr. Bréchot’s research has been focused on viral hepatitis: hepatitis B (HBV) and C (HCV) and their role in liver cancer and on the molecular mechanisms that drive liver regeneration and cancer. He has also investigated the role of a C-type lectin in resistance to insulin, diabetic neuropathy and Alzheimer’s diseases. Dr. Bréchot is the author of over 400 articles with a current H factor of over 100. He holds 18 patents and has contributed to the creation of three biotech companies: Rarecells, The Healthy Aging Company, and now Blue Zone Therapeutics.

---

Advisory Board

Dr. Jon P. Mochel is a Professor of Systems Pharmacology in the Department of Pathology and the Founding Director of the Precision One Health Initiative at the University of Georgia (USA). He has an extensive background in Clinical and Basic Pharmacology and Toxicology and is a Board-Certified Veterinary Pharmacologist and Toxicologist (DECVPT). Dr. Mochel holds advanced degrees in Pharmacology (MS), Pharmacokinetics (MS), and Applied Mathematical Modeling (PhD). His research focuses on the effects of therapeutic drugs in complex biological systems, such as the heart and kidneys.

Dr. Mochel is a Fellow of the American Academy of Veterinary Pharmacology and Therapeutics and serves as an ad hoc reviewer for several public organizations, including the US National Science Foundation, the National Institute of Standards and Technology, the UK Medical Research Council, and the CNRS/INSERM ATIP-Avenir Program. His contributions have earned him the Early Career (2019) and Mid-Career Achievement (2022) Research Awards from Iowa State University’s College of Veterinary Medicine, as well as the American Academy of Veterinary Pharmacology Research Award (2022).

Dr. Mochel currently serves as President of the European Association of Veterinary Pharmacology and Toxicology (EAVPT) and as the President Elect of the European College of Veterinary Pharmacology and Toxicology (ECVPT). He has authored over 160 peer-reviewed publications in select biomedical journals and has secured more than $17 million in research funding as a principal investigator ($8,107,188) or co-investigator ($9,187,951) in the past eight years. As of 2024, Dr. Mochel is recognized as one of the “World’s Top 2%” scientists on Stanford University’s list.

---

Dr. Alain Cosnier is a seasoned executive with deep expertise in veterinary health and product innovation. He previously held multiple leadership roles at Vetoquinol, including Director of Innovation and Development, Director of Sales and Marketing, and Director of Business Development, where he helped shape strategic growth and product launches in the companion animal sector. He also served as Director of Innovation and Development at Ceva Santé Animale, focusing on OTC product lines for pets.

With a veterinary degree from the École Nationale Vétérinaire de Toulouse and an MBA in marketing from EM Lyon, Dr. Cosnier combines scientific insight with commercial acumen. His global perspective, entrepreneurial mindset, and strong industry network make him an ideal leader for business development as the company advances novel therapies for chronic diseases in pets.